News & Updates
Filter by Specialty:
OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies
Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.
OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies
05 Mar 2024
Semaglutide induces weight loss despite antidepressant use
Treatment with semaglutide 2.4 mg results in clinically meaningful weight loss, irrespective of baseline antidepressant (AD) use, among adults with overweight/obesity, reports a post hoc study of the Semaglutide Treatment Effect for People with obesity (STEP).
Semaglutide induces weight loss despite antidepressant use
03 Mar 2024
Trastuzumab deruxtecan shows promise in metastatic breast cancer
Treatment with trastuzumab deruxtecan (T-DXd) provides sustained antitumour activity and shows a consistent safety profile in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1), as shown by the updated survival results from the phase II DESTINY-Breast01 trial.
